Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255979 | 0.79 | CYP2A6 (0.71) | CYP2A6KEAP1NFE2L2CA2HDAC10 | |
| SCHEMBL246112 | 0.78 | CYP2A6 (0.69) | CYP2A6KEAP1NFE2L2CA2SMN1; SMN2 | |
| SCHEMBL3276210 | 0.78 | CA2 (0.55) | CYP2A6KEAP1NFE2L2CA2 | |
| SCHEMBL2114297 | 0.78 | CA2 (0.55) | CYP2A6KEAP1NFE2L2CA2SMN1; SMN2 | |
| SCHEMBL7340610 | 0.74 | MTNR1A (0.57) | CYP2A6MTNR1AMTNR1BKDM4E | |
| SCHEMBL30003342 | 0.72 | CYP2A6 (0.67) | CYP2A6CA2SMN1; SMN2 | |
| SCHEMBL2792315 | 0.72 | CYP2A6 (0.67) | CYP2A6CA2SMN1; SMN2 | |
| SCHEMBL2091136 | 0.71 | CYP2A6 (0.60) | CYP2A6CA2 | |
| SCHEMBL2092119 | 0.71 | CYP2A6 (0.33) | CYP2A6 | |
| SCHEMBL7744805 | 0.69 | MTNR1A (0.36) | CYP2A6KEAP1NFE2L2CA2MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009102384-A2 | RADIOLABELED DERIVATIVES OF POTENT CHYMASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090169475-A1 | RADIOLABELED DERIVATIVES OF POTENT CHYMASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090169475-A1 | RADIOLABELED DERIVATIVES OF POTENT CHYMASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169475-A1 | RADIOLABELED DERIVATIVES OF POTENT CHYMASE INHIBITORS | CMA1, CPA3, CPA1 | CYP2A6 1801/4885KEAP1 1462/4885NFE2L2 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.